InnoPharma raises $8M in venture debt

Monday, June 11, 2012 12:04 PM

InnoPharma, a sterile product development company of Piscataway, N.J., has closed on an $8 million growth capital financing from Comerica Bank and NXT Capital Venture Finance.

Proceeds from the financing will provide additional working capital and will support the InnoPharma's ongoing development of niche generic and specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as strategic advisors to InnoPharma for this transaction.

"InnoPharma has a robust pipeline of unique specialty pharmaceutical products and the team has made great strides tackling many of the formulation challenges currently facing drug developers," said Jeff Chapman, senior vice president at Comerica Bank.

Peter Fair, managing director of NXT Capital Venture Finance, added, "InnoPharma's management team has a unique blend of top-notch drug development experience coupled with strong business acumen. We are extremely pleased to provide a flexible financing solution to a company with such demonstrated talent for producing complicated drugs that service significant market needs."

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs